DOI: 10.1002/ccr3.72855 ISSN: 2050-0904
Efficacy of Disitamab Vedotin in Treating
HER
2 2+/
FISH
‐Bladder Cancer: A Case Report
Zhi‐ruo Jin, Cheng‐yong Dong, Yu‐jun Li, Yang Zou, Xi‐mei Wang, Hui‐ying Li, Gang Wang, Xiao‐nan Cui, Ying Liu ABSTRACT
Disitamab Vedotin achieved durable partial response (> 8 months PFS) in advanced HER2 2+/FISH‐ bladder cancer after first‐line chemo‐immunotherapy progression. This case provides real‐world evidence that disitamab vedotin may benefit HER2 2+/FISH‐ patients, supporting broader HER2 testing and treatment consideration in this subset.